Test Name
FLT3 Mutation Analysis
Test Code
M FLT3*
Synonyms
FLT3 gene, ITD mutation
Associations
Acute myelogenous leukemia (AML)
Reflex Testing
FLT3 is ordered as part of the AML mutational profile.
CPT Codes
81245, 81479
Turnaround Time
10 days
Specimen Requirements
5.0 mL (min. 3.0 mL) whole blood or (min. 2.0 mL) bone marrow EDTA, Sodium Heparin or ACD
Specimen Stability
Stable 18-25°C for 1 week Stable 4°C up to 14 days
Storage & Handling
Ship at ambient temperature, cool in summer. (Do not allow cool/refrigerated pack to directly contact sample.)
Causes for Rejections
Improper specimen labeling; Insufficient sample volume; Clotted specimen; Specimen older than 7 days
Description
Intended for use as a screening test in patients with AML to assist with stratification and selection of post-remission therapies. Internal tandem duplications in exons 14 and 15 of the FMS-related tyrosine kinase 3 (FLT3) gene are found in ~30% of cytog
References
- Acute myeloid leukemia, NCCN clinical practice guidelines in oncology (2008).
- Mrozek K et al. (2007). Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood. 109:431-448.
- Meshinchi S et al. (2006). Clinical implications of FLT3 mutation in pediatric acute myeloid leukemia. Blood. 108(12):3654-3661.
- Kiyoi H and Naoe T. (2006). Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation. Int J Haematol. 83(4):301-308.
- Fohling S et al. (2005). Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol. 23(26):6285-6295.
- Kiyoi H et al. (2005). Clinical significance of FLT3 in leukemia. Int J Haematol. 82(2):85-92.
- Yamamoto Y et al. (2001). Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 97(8):2434-2439.
